10.85
Helix Acquisition Corp Ii stock is traded at $10.85, with a volume of 1,417.
It is up +0.00% in the last 24 hours and up +1.78% over the past month.
Helix Acquisition Corp II is a Blank check company.
See More
Previous Close:
$10.85
Open:
$10.91
24h Volume:
1,417
Relative Volume:
0.03
Market Cap:
$255.07M
Revenue:
-
Net Income/Loss:
$3.27M
P/E Ratio:
64.62
EPS:
0.1679
Net Cash Flow:
$-647.10K
1W Performance:
-0.09%
1M Performance:
+1.78%
6M Performance:
+2.99%
1Y Performance:
+4.93%
Helix Acquisition Corp Ii Stock (HLXB) Company Profile
Name
Helix Acquisition Corp Ii
Sector
Industry
Phone
857 702 0377
Address
C/O CORMORANT ASSET MANAGEMENT, LP, BOSTON
Compare HLXB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HLXB
Helix Acquisition Corp Ii
|
10.85 | 255.07M | 0 | 3.27M | -647.10K | 0.1679 |
![]()
LION
Lionsgate Studios Corp
|
7.22 | 2.06B | 0 | 0 | 0 | 0.00 |
![]()
AACT
Ares Acquisition Corporation Ii
|
11.27 | 697.16M | 0 | 16.92M | -1.35M | 0.29 |
![]()
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.75 | 461.44M | 0 | 1.30M | 0 | 0.0301 |
![]()
EQV
Eqv Ventures Acquisition Corp
|
10.23 | 455.09M | 0 | 0 | 0 | 0.00 |
Helix Acquisition Corp Ii Stock (HLXB) Latest News
Geode Capital Management LLC Acquires 119,943 Shares of Nuburu, Inc. (NYSEAMERICAN:BURU) - Defense World
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
Geode Capital Management LLC Increases Stock Holdings in Helix Acquisition Corp. II (NASDAQ:HLXB) - Defense World
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
German cancer antibody biotech eyes SPAC as route to Nasdaq - Fierce Biotech
Harraden Circle Investments LLC Acquires Shares of 257,226 Helix Acquisition Corp. II (NASDAQ:HLXB) - MarketBeat
Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan - Yahoo Finance
MLTX stock touches 52-week low at $36.51 amid market shifts - Investing.com Australia
MLTX stock touches 52-week low at $36.51 amid market shifts By Investing.com - Investing.com South Africa
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire
Firm foundations: Can US IPO markets continue to build on solid gains? - Lexology
Decagon Asset Management LLP Invests $1.96 Million in Helix Acquisition Corp. II (NASDAQ:HLXB) - MarketBeat
Newsroom - White & Case LLP
GSK’s $1.15B Idrx buyout leads slow M&A market as deals stay strong - BioWorld Online
Bay Area VC-funded life sciences companies raised over $5 billion in 2024 - The Business Journals
Helix Exploration expands with key acquisition at Rudyard - Proactive Investors
Helix Acquisition Corp. II SEC 10-K Report - TradingView
MLTX stock touches 52-week low at $37.53 amid market shifts - Investing.com Australia
BBIOBridgebio Pharma Latest Stock News & Market Updates - StockTitan
Helix Acquisition Corp. II’s US$949 Million Business Combination with BridgeBio Oncology Therapeutics - Global Legal Chronicle
BridgeBio Oncology and Helix enter definitive merger agreement - MSN
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
White & Case advises Helix Acquisition Corp. II on its US$949 million business combination with BridgeBio Oncology Therapeutics - White & Case LLP
Helix Acquisition Corp. II (HLXB) to Combine with BridgeBio Oncology in $360M Deal - SPACInsider
Helix Acquisition Corp. II Merger with BridgeBio Oncology Therapeutics - Leerink Partners
Helix Acquisition Corp. II PIPE - Leerink Partners
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - insights.citeline.com
LZ Technology Closes $7.2 Million IPO -February 28, 2025 at 04:48 pm EST - Marketscreener.com
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - MedCity News
Boston SPAC picks biotech to take public - The Business Journals
Goodwin, White & Case Build BridgeBio's $949M SPAC Deal - Law360
BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal - BioSpace
Helix Acquisition to Merge With BridgeBio Oncology Therapeutics - MarketScreener
BridgeBio's KRAS-focused cancer spinout backs SPAC as path to Nasdaq - Fierce Biotech
BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II To Merge - citybiz
BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen - Endpoints News
$450M Deal Powers New Cancer-Fighting Biotech: What's Inside BridgeBio's Oncology SPAC Merger? - StockTitan
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public - The Business Journals
Fifth Era Acquisition Corp. I (FERAU) Prices $200M IPO - SPACInsider
NewHold Investment Corp. III (NHICU) Prices $175M IPO - SPACInsider
Live Oak Acquisition Corp. V (LOKVU) Prices $200M IPO - SPACInsider
Wall Street Sentiment Positive After Nvidia Earnings, Lifting US Equity Futures Pre-Bell - Marketscreener.com
Rithm Acquisition Corp. (RAC.U) Prices $200M IPO - SPACInsider
Helix Acquisition Corp. II appoints new independent director - MSN
Blank Check Co Sichuan Hongyi Enterprise Management Co Ltd Files For IPO Of Up To $100 Mln - Marketscreener.com
Podcast: Inside the Private Markets with Nick Fusco, Founder & CEO of PM Insights - SPACInsider
EQT has sold Waystar shares for $ 393 million -February 25, 2025 at 12:34 am EST - Marketscreener.com
10 Oversold Pharma Stocks to Buy According to Analysts - Insider Monkey
KKR plans $2 billion sale of BMC Helix - Traders Union
Helix Acquisition Corp Ii Stock (HLXB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):